Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Seipel

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Acta Haematologica|March 6, 2024
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity after Supportive Stem Cell Boost in Multiple MyelomaAlexander D Heini, Vera Ulrike Bacher, Dilara Akhoundova, et al.
Cancers|June 10, 2023
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell TherapyKatja Seipel, Mariesol Abbühl, Ulrike Bacher, et al.
Cancers|June 3, 2018
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid LeukemiaKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Cancers|May 27, 2026
Elevated Allele Frequency of a Common Germline <i>LAG3</i> Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid LeukemiaKatja Seipel, Inna Shaforostova, Elisa Tarozzi, et al.
Cancers|June 12, 2026
Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World ExperienceTina Schmid, Inna Shaforostova, Ulrike Bacher, et al.
Cancers|June 12, 2026
Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell TransplantationElisa Tarozzi, Katja Seipel, Inna Shaforostova, et al.
Cancers|July 15, 2026
Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell LymphomaSimona Andrea Ruckstuhl, Katja Seipel, Inna Shaforostova, et al.
Cancers|May 27, 2026
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World StudyInna Shaforostova, Marie-Noelle Kronig, Katja Seipel, et al.
Current Issues in Molecular Biology|June 20, 2022
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple MyelomaKatja Seipel, Naomi Porret, Gertrud Wiedemann, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Acta Haematologica|March 6, 2024
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity after Supportive Stem Cell Boost in Multiple MyelomaAlexander D Heini, Vera Ulrike Bacher, Dilara Akhoundova, et al.
Cancers|June 10, 2023
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell TherapyKatja Seipel, Mariesol Abbühl, Ulrike Bacher, et al.
Cancers|June 3, 2018
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid LeukemiaKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Cancers|May 27, 2026
Elevated Allele Frequency of a Common Germline <i>LAG3</i> Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid LeukemiaKatja Seipel, Inna Shaforostova, Elisa Tarozzi, et al.
Cancers|June 12, 2026
Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World ExperienceTina Schmid, Inna Shaforostova, Ulrike Bacher, et al.
Cancers|June 12, 2026
Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell TransplantationElisa Tarozzi, Katja Seipel, Inna Shaforostova, et al.
Cancers|July 15, 2026
Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell LymphomaSimona Andrea Ruckstuhl, Katja Seipel, Inna Shaforostova, et al.
Cancers|May 27, 2026
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World StudyInna Shaforostova, Marie-Noelle Kronig, Katja Seipel, et al.
Current Issues in Molecular Biology|June 20, 2022
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple MyelomaKatja Seipel, Naomi Porret, Gertrud Wiedemann, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Pageof 8